Pulmonary Hypertension Due to Lung Disease (Disorder)
—
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Pulmonary hypertension associated with interstitial lung disease (PH-ILD)(Approved)
Pulmonary hypertension associated with COPD (PH-COPD)(Stage not disclosed)
Idiopathic pulmonary fibrosis (IPF)(Stage not disclosed)
Progressive pulmonary fibrosis (PPF)(Stage not disclosed)
Raynaud's phenomenon associated with systemic sclerosis (SSc-RP)(Stage not disclosed)
Status note FDA approved May 2025 for PAH and PH-ILD; commercialized June 2025 (deep-lung delivery via PRINT-engineered particles, low-effort DPI, higher dose levels than other inhaled treprostinil). Additional indications (PH-COPD, IPF, PPF, SSc-RP) in planning. Ongoing United Therapeutics litigation seeks YUTREPIA's removal from the market.
Partnerships Pharmosa Biopharm: exclusive license ($13.5M upfront total; up to $37.75M dev milestones in PAH/PH-ILD; up to $185M NA + $150M ex-NA sales milestones; two tiers of low double-digit royalties). Vectura: exclusive US license for nebulizer device ($2M upfront; up to $12M dev milestones; up to $92.5M sales milestones; mid single-digit royalties)
Indications
Pulmonary hypertension associated with interstitial lung disease (PH-ILD)(Phase 3)
Pulmonary arterial hypertension (PAH)(Phase 3)
Status note In open-label study in the US (PAH and PH-ILD) and a worldwide placebo-controlled pivotal study (PH-ILD). No dated readout stated in this filing.
Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Pipeline
Lead drug
L606
Lead indication
Pulmonary Hypertension Due to Lung Disease (Disorder)
Sponsor-matched active trials from ClinicalTrials.gov (6 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.